Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

Biologic-based therapeutics are known to generate anti-drug immune responses or immunogenicity in clinical patients which can lead to altered pharmacokinetics, decreased drug efficacy, and unwanted ...

Assessing immunogenicity is a cornerstone of modern drug development, especially for biologics and vaccines. Understanding how the immune system interacts with therapeutic agents is essential to ...

In the vaccine efficacy and preclinical safety space, this includes immunogenicity assays, neurovirulence testing, antibody-dependent enhancement and vaccine-associated enhanced disease models and ...

At PEPperPRINT, we developed a novel pipeline to enable: Profiling potential T-cell immunogenicity through chip-based MHC-associated peptide proteomics (MAPPs) assay Discrimination of regulatory T ...

Serum samples for anti-panitumumab antibody testing were collected from mCRC patients enrolled in 4 panitumumab clinical trials (20050184, 20060277, 20050181, and 20050203). Patients in these ...

Immunogenicity bioanalysis follows an industry-standard tiered-testing approach, including assay screening (all samples), ...

PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by ...

PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by ...

Comparing the immunogenicity of currently used TNF-α ... making it difficult or impossible for a drug-sensitive assay to detect anti-etanercept antibodies. One approach to overcome this problem ...